MedTrace Logo

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

NCT05266469 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2025-07-09

No results posted yet for this study

Summary

This is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one year to collect their profiles across the Gulf countries.

Conditions

Interventions

OTHER

Ofatumumab

There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.

OTHER

Ocrelizumab

There is no treatment allocation. Patients administered Ocrelizumab by prescription will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2024-11-11
Completion
2024-11-11

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05266469 on ClinicalTrials.gov